Tesaro Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
715
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$5B
Tesaro General Information
Description
Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.
Contact Information
Website
www.tesarobio.comCorporate Office
- 1000 Winter Street
- Waltham, MA 02451
- United States
Corporate Office
- 1000 Winter Street
- Waltham, MA 02451
- United States
Tesaro Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 22-Jan-2019 | $5B | Completed | Profitable | ||
| 9. Secondary Transaction - Open Market | 01-Jun-2018 | Completed | Profitable | |||
| 8. PIPE | 01-Jan-2018 | Completed | Generating Revenue | |||
| 7. Debt - General | 01-Nov-2017 | Completed | Profitable | |||
| 6. 2PO | 01-Jul-2016 | Completed | Generating Revenue | |||
| 5. PIPE | 18-Apr-2016 | Completed | Generating Revenue | |||
| 4. 2PO | 27-Feb-2013 | Completed | Generating Revenue | |||
| 3. IPO | 28-Jun-2012 | Completed | Clinical Trials - Phase 3 | |||
| 2. Early Stage VC (Series B) | 21-Jun-2011 | $101M | $121M | Completed | Product Development | |
| 1. Early Stage VC (Series A) | 26-May-2010 | $20M | $20M | Completed | Product Development |
Tesaro Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Tesaro Comparisons
Industry
Financing
Details
Tesaro Competitors (73)
One of Tesaro’s 73 competitors is OncBioMune, a Corporate Backed or Acquired company based in Baton Rouge, LA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| OncBioMune | Corporate Backed or Acquired | Baton Rouge, LA | ||||
| Acerus Pharmaceuticals | Corporation | Mississauga, Canada | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Lubrizol Particle Sciences | Corporate Backed or Acquired | Bethlehem, PA | ||||
| Cipla | Corporation | Mumbai, India |
Tesaro Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tesaro Patents
Tesaro Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202404449-D0 | Novel use | Pending | 28-Mar-2024 | ||
| GB-202316472-D0 | Novel use | Pending | 27-Oct-2023 | ||
| GB-202307322-D0 | Novel use | Inactive | 17-May-2023 | ||
| EP-4479050-A1 | Use of niraparib for the treatment of brain cancer | Pending | 15-Feb-2022 | ||
| US-20240366584-A1 | Combination treatment of cancer with a parp inhibitor and a lipophilic statin | Pending | 21-Jun-2021 | A61K31/454 |
Tesaro Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tesaro Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ally Bridge Group | PE/Buyout | Minority | ||
| Athyrium Capital Management | Asset Manager | Minority | ||
| Australia Future Fund | Sovereign Wealth Fund | Minority | ||
| BB Biotech | Asset Manager | Minority | ||
| BioPharma Credit | Lender/Debt Provider | Minority |
Tesaro Investments (1)
Tesaro’s most recent deal was a Later Stage VC with TeneoBio for . The deal was made on 08-Jan-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TeneoBio | 08-Jan-2018 | Later Stage VC | Biotechnology |
Tesaro ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Tesaro FAQs
-
When was Tesaro founded?
Tesaro was founded in 2010.
-
Where is Tesaro headquartered?
Tesaro is headquartered in Waltham, MA.
-
What is the size of Tesaro?
Tesaro has 715 total employees.
-
What industry is Tesaro in?
Tesaro’s primary industry is Pharmaceuticals.
-
Is Tesaro a private or public company?
Tesaro is a Private company.
-
What is the current valuation of Tesaro?
The current valuation of Tesaro is .
-
What is Tesaro’s current revenue?
The current revenue for Tesaro is .
-
How much funding has Tesaro raised over time?
Tesaro has raised $1.61B.
-
Who are Tesaro’s investors?
Ally Bridge Group, Athyrium Capital Management, Australia Future Fund, BB Biotech, and BioPharma Credit are 5 of 19 investors who have invested in Tesaro.
-
Who are Tesaro’s competitors?
OncBioMune, Acerus Pharmaceuticals, Novartis, Lubrizol Particle Sciences, and Cipla are some of the 73 competitors of Tesaro.
-
When was Tesaro acquired?
Tesaro was acquired on 22-Jan-2019.
-
Who acquired Tesaro?
Tesaro was acquired by GSK.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
